Содержание

1. Анатомо-физиологические особенности костной ткани
2. Ремоделирование костной ткани
3. Влияние половых гормонов на костную ткань
4. Остеопороз: введение
5. Факторы риска развития остеопороза
6. Классификация остеопороза
7. Клиника остеопороза
8. Диагностика остеопороза
9. Лечение и профилактика
10. Литература

Список литературы

1. Дедов И.И., Марова Е.И., Рожинская Л.Я. Остеопороз: патогенез, диагностика, принципы профилактики и лечения; Методическое пособие для врачей. М., 1999- 63 с.
2. Ермакова И.П., Пронченко И.А. Современные биохимические маркеры в диагностике остеопороза // Остеопороз и остеопатии. 1998. 2.
3. Сметник В.П. Принципы заместительной гормональной терапии при климактерических расстройствах // Акушерство и гинекология. 1995. 3. С. 15 - 17.
4. Сметник В.П. Постменонаузальный остеопороз: принципы заместительной гормонотерапии // Остеопороз и остеопатии. 1998. 2. С. 21 - 24.
5. Сметник В.П. Гинекологическая эндокринология.// Руководство для врачей, 1997. - 460 с.
6. Рожинская Л.Я. Системный остеопороз: Практич. рук-во для врачей.// М.: Издатель Мокеев, 2000. 195 с.
7. Рожинская Л.Я. Остеопенический синдром при нейроэндокринных заболеваниях // Нейроэндокринология / Под ред. Е,И. Маровой. Ярославль, 1999. С. 423 - 484.
8. Рожинская Л.Я. Постменопаузальный и сенильный остеопороз: современные возможности диагностики, профилактики и лечения // Consilium medicum, 2003. т.5, N12
9. Шумаков В.И., Мойсюк Я.Г., Томилина И.А., Ермакова И.П. Трансплантация почки. Нарушения минерального обмена // Трансплантология / Руководство под ред. В. И. Шумакова. Москва "Медицина", Тула "Репроникс Лтд." - 1995. - Частная Трансплантология. Глава 17 - стр. 183 - 211.
10. Ammann P., Rizzoli R., Bonjour J.P., et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency // J din Invest. 1997. V. 99. 7. P, 1699 - 1703.
11. Baltazar G., Ardakani S., Dean J.J., Carelli M.J., Daniloff G.Y. and Kung V.T. Monoclonal Antibody assay for measuring bone-specific alkaline phosphatase in serum // Clin Chem 1995; 41: 1560-1566.
12. Bettica P., Moro L. Biochemical markers of bone metabolism in the assessment ofosteoporosis // JIFCC 1995. V. 7, issue 1, p. 16 - 22.
13. Cosman F., Shen V., Xie F., et al. Estrogen protection against bone resorbing effect of parathyroid hormone infusion // Ann Intern Med. 1993. V. 118. P. 337 - 343.
14. Cooper C, Campion. G., Hip L.J Fractures in the Elderly: a Word-wide Projection. Osteoporosis int., 1992, 2; P. 285-289.
15. David. W., Dempstek D, Robert Lindsay Патогенез остеопороза. The Lanscet - vol. 34, March 27, 1993.
16. Dempster D.W., Birchman R., Xu R., et al. Temporal changes in cancellous bone structure of rats immediately after ovariectomy // Bone. 1995. V. 16, 1. P. 157 - 161.
17. Dempster D.W. and Lindsay R. (1993), Pathogenesis ofosteoporosis // Lancet 1993; 341:797-801.
18. DM. J Med Consensus Development Conference: Profilaxis and Treatment of Osteoporosis, 1993; 94: 646-650.
19. Eriksen E.F., Colvard D.S., Berg N.J. et al. Evidence of estrogen receptors in normal human osteoblast-like cells // Science. 1988. V. 241. P. 84 - 86.
20. Ebeling P. R., Peterson J. M., Riggs B. L. "Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases" // J of Bone and Mineral Research 1992, v. 7, # 11, р. 1243 - 1250.
21. Ettinger B., Genant U.K., Steiger P., Madvig P. Low dosage micronized 17p-estradiol prevents bone loss in postmenopausal women // Am J Obstel Gynecol. 1992. V. 166, P. 479 - 488.
22. Franks S., D.M. White. Gonadotropin insufficiency in women: diagnosis and treatment // The diagnosis and treatment of pituitary insufficiency, S.W.J.Lamberts, "BioScien-tifica",1997. P. 131 - 138.
23. Frost H.M. On the esrtogen-bone relationship and postmenopausal bone loss: a new model // J Bone Miner Res. 1999. V. 14, 9. P. 1473 - 1477.
24. Guo C.Y., Jones Т.Н., Eastell R. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover // J Clin Endocrinol Metab. 1997 Feb. V. 82, 2. P. 658 - 665.
25. Favus M. J. Ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism // Raven Press. New York. - 1995. - pp. 1200.
26. Jameson J.L. Inherited disorders of the gonadotropin hormones // Mol Celt Endocrinol. 1996. V. 125, 1-2. P. 143 - 149.
27. Jilka R., Hangoc G., Girasole G., et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6 // Science. V. 257. P. 88 - 91.
28. Johnson. C.C.Jr., Miller J.Z. Slemenda C.W et al. Calcium Supplementation and increases in bone minerals density in children. N Engl. J. Med. 1992; 327: 382-387.
29. Kanis J,A. Pathogenesis of osteoporosis and fracture // In: Osteoporosis. BlackwellHeallh-care Communications. 1997. P. 22 - 55.
30. Kanis J.A.. Johnell O., Gullberg B., et al. Evidence for efficacy of drugs affecting bone mctaboism in preventing hip fracture // Br Med J. 1992. V. 305. P. 1124 - 1128.
31. Kimble R.B. Alcohol, cytokines, and estrogen in the control of bone remodeling // Alcohol Clin Exp Res, 1997. V. 21, N3 P. 385 - 391.
32. Lees B., Pugh M., Siddle N., Stevenson J.C. Changes in bone density in women starting hormonal replacement therapy compared with those in women already established on hormonal replacement therapy // Osteoporosis Int 1, 1995. V. 5. P. 344 - 348.
33. Layman L.C. Mutations in human gonadotropin genes and their physiologic significance in puberty and reproduction // Fertil Steril 1999 Feb; V. 71, N2, P. 201 - 218.
34. Layman L.C. The molecular basis of human hypogonadotropic hypogonadism // Mol. Genet. Metab.- 1999 Oct. V. 68, MO 2. P. 191 - 199.
35. Lindsay R. Estrogen deficiency. In: Osteoporosis: Etiology, Diagnosis and Management, (ed. Riggs B.L), New York. Raven Press. 1995. P. 133 - 160.
36. Lindsay R. The estrogen receptor in bone. Evolution of knowledge // Br J Obstet Gynecol. 1996. V. 13. P. 16 - 19.
37. Mohan S. Baylink D. Bone Growth Factors. Chin Orthop. Rel.Res. 1991, 263.3048.
38. Naessen T., Persson I., Adami H.O., et al. Hormone relacement therapy and the risk for first hip fracture // Annals Int Med, 1990. V. 113. P. 95 - 103.
39. Natsume H., Nakamura H. Hypogonadism and osteoporosis //NipponRinsho, 1998 Jun. V. 56, Mo. 6. P. 1613-1617.
40. Oikarinen A., Autio P., Vuori J., Vaananen K., Risteli L., Kistala U., Risteli J. "Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen" // British J of Dermatology 1992, v. 126, р. 172 - 178.
41. Parfitt A.M., Mathews C.H.E., Villanueva A.R. et al. Relationships between surface volume and thickness of iliac trabecular bone in ageing and osteoporosis // J Clin Invest, 1983. V. 72. P. 1396- 1409.
42. Parfut D.M. Implications of Architecture for the Pathogenesis and Prevention of Vertebral Fracture. Bone 1992, 13: P. 41-47.
43. Рагfut A.M. Bone Remodelling; Relationship to the Arrount the Structure of Bone and the Pathogenesis and Prevention of Fractures In: Riggs B.L., Melton L.J. eds. "Osteoporosis: Etiology, Diagnosis and Management" New York: Raven 1998: 355 p.
44. Price С. P. and Thompson P.W. The role of biochemical tests in the screening and monitoring ofosteoporosis // Ann Clin Biochem 1995; 32:244-260.
45. Riggs B.L. Osteoporosis. In: Wyngaarden J.B.Jk Smith L.H. eds. "Cecil textbook of Medicine" Philadelphia, WB.Saunders, 1988, 1510.
46. Riggs B.L., Khosia S., Melton L.J. A unitary model for involutional osteoporosis: estrogen deficiency causes both type 1 and type 11 osteoporosis in postmenopausal women and contributes to bone loss in aging men [see comments] // J Bone Miner Res, 1998. V. 13, N5. P. 763 - 773.
47. Seibel M.J., Robins S.P. and Beiezikian J.P, Urinary pyridinoline crosslinks of collagen // Trends in Endocrinology and Metabolism 1992; 3(7): 263-278.
48. Shen V., Birchman R., Xu R.. et al. Short-term changes in histomorphomctric and biochemical turnover markers and bone mineral density in estrogen-and/or dietary calcium deficient rats // Bone, 1995. V. 16, N1. P. 149 - 156,
49. Thomer M.O., Vance M.L., Laws E.R. et al. The anterior pituitary // In Williams Textbook of Endocrinology 9th edition. Philadelphia: WB Saunders. 1998. P. 249 - 340.
50. Valimaki M.J., Tahtela R., Jones J.D., Peterson J.M., Riggs B.L. Bone resorption in healthy and osteoporosis postmenopausal women // Eu J Clin Endocrin 1994; 131; 258-262.
51. Van der Mooren M.J., Dcmacker P.N.M., Thomas C.M.G., et al. A 2-year study on the beneficial effects of 17p-estradiol-dydrogesleronc therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesteron / Eur J Obst Gyn Reprod Biology. 1993. V. 52. P. 117-123.
52. Van Hoof H., van der Moren M., Swinkels L., et al. Hormone replacement therapy increases scrum 1,2 5-dihydroxy vitamin D: a 2-ycar prospective study // Calcified Tissue Int, 1994. V. 55. P. 417 - 419.
53. Vaananen H.K., Harkonen P.L. Estrogen and bone metabolism // Maturitas, 1996. V. 23, suppi: S 65 - 69.
54. Valimaki M. J., Tantela R., Jones J. D., Peterson J. M., Riggs BL. "Bone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links" //EurJ Endocrinol 1994, v. 131, p. 258 - 262.
55. Verhaar H.J.L, Damen C.A., Duursma Scheven B.A.A. A comparison of action of pro-gestins and estrogen on the growth and differentiation of normal adult human osteoblasl-like cells in vitro. 11 Bone, 1994. V. 15. P. 307 - 311.
56. Voetberg G.A., Netelenbos J.C., Kcnemans P., et al. Estrogen replacement therapy con-tinuosly combined with four different dosages of dydrogesteronc; effect on calcium and lipid metabolism // J Clin Endocrin Metab - 1994, V. 79. P. 1465 -1469.
57. Yermakova I.P., Pronchenko I.A., BuzulinaV. p., Rekina I.V. "Biochemical features of osteoporosis (OP) following kidney transplantation" // World Congress on Osteoporosis, Amsterdam, 18-23 May, 1995. Osteoporosis International. Eds. R. Lindsay&P.J. Meunier.Vol. 6, Suppl. 1, 1996, PTu 763, p. 273.
58. Wren B.G. Megatrials of hormonal replacement therapy // Drugs and Aging, 1998. V. 12, Mo 5. P. 343 - 348.
59. Withold W., Degenhardt S., Castelli D., Heins M., Grabensee B. "Monitoring of osteoblast activity with an immunoradiometric assay for determination of bone alkaline phosphatase mass concentration in patients receiving renal transplan-tats"//ClinicaChimicaActa 1994, v. 225, p. 137- 146.